Role of RNA modifications in blood development and regeneration
- PMID: 39009277
- PMCID: PMC11415282
- DOI: 10.1016/j.exphem.2024.104279
Role of RNA modifications in blood development and regeneration
Abstract
Blood development and regeneration require rapid turnover of cells, and ribonucleic acid (RNA) modifications play a key role in it via regulating stemness and cell fate regulation. RNA modifications affect gene activity via posttranscriptional and translation-mediated mechanisms. Diverse molecular players involved in RNA-modification processes are abundantly expressed by hematopoietic stem cells and lineages. Close to 150 RNA chemical modifications have been reported, but only N6-methyl adenosine (m6A), inosine (I), pseudouridine (Ψ), and m1A-a handful-have been studied in-cell fate regulation. The role of RNA modification in blood diseases and disorders is an emerging field and offers potential for therapeutic interventions. Knowledge of RNA-modification and enzymatic activities could be used to design therapies in the future. Here, we summarized the recent advances in RNA modification and the epitranscriptome field and discussed their regulation of blood development and regeneration.
Published by Elsevier Inc.
Conflict of interest statement
Conflict of Interest Disclosure Dr LI Zon is a Howard Hughes Medical Institute investigator. The other author does not have any conflicts of interest to declare in relation to this work.
Similar articles
-
The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities.Mol Cancer. 2021 Jan 18;20(1):18. doi: 10.1186/s12943-020-01263-w. Mol Cancer. 2021. PMID: 33461542 Free PMC article. Review.
-
m6A RNA modifications: Key regulators of normal and malignant hematopoiesis.Exp Hematol. 2022 Jul;111:25-31. doi: 10.1016/j.exphem.2022.04.006. Epub 2022 Apr 27. Exp Hematol. 2022. PMID: 35487293 Review.
-
Writers, readers, and erasers RNA modifications and drug resistance in cancer.Mol Cancer. 2024 Aug 30;23(1):178. doi: 10.1186/s12943-024-02089-6. Mol Cancer. 2024. PMID: 39215288 Free PMC article. Review.
-
Exploring the epitranscriptome by native RNA sequencing.RNA. 2022 Nov;28(11):1430-1439. doi: 10.1261/rna.079404.122. Epub 2022 Sep 14. RNA. 2022. PMID: 36104106 Free PMC article.
-
Epitranscriptomics in Hematopoiesis and Hematologic Malignancies.Blood Cancer Discov. 2020 Jun 22;1(1):26-31. doi: 10.1158/2643-3249.BCD-20-0032. eCollection 2020 Jul. Blood Cancer Discov. 2020. PMID: 34661141 Free PMC article. Review.
Cited by
-
Leveraging genetics to understand ADAR1-mediated RNA editing in health and disease.Nat Rev Genet. 2025 Aug;26(8):532-546. doi: 10.1038/s41576-025-00830-5. Epub 2025 Apr 14. Nat Rev Genet. 2025. PMID: 40229561 Review.
References
-
- Geula S, Moshitch-Moshkovitz S, Dominissini D, Mansour AA, Kol N, Salmon-Divon M, et al. m6A mRNA methylation facilitates resolution of na{\”\i}ve pluripotency toward differentiation. Science (80- ) [Internet]. 2015;347:1002–6. Available from: http://science.sciencemag.org/content/347/6225/1002 - PubMed
-
- Zhao B, Nachtergaele S, Roundtree IA, He C. Our views of dynamic N 6 -methyladenosine RNA methylation. Rna [Internet]. 2017;rna.064295.117. Available from: http://rnajournal.cshlp.org/lookup/doi/10.1261/rna.064295.117%0Ahttp://r... - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources